Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%

Abstract

AbstractBackgroundImmune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non‐small cell lung cancer (NSCLC) patients with programmed death ligand‐1 (PD‐L1) expression ≥50%. However, the efficacy of ICI monotherapy in patients with PD‐L1 expression <50% has not yet been fully elucidated.The aim of this study was to identify the clinical characteristics of NSCLC patients with PD‐L1 expression <50% who respond to single‐agent ICIs and factors that predict response.MethodsPatients with advanced or recurrent NSCLC with a PD‐L1 tumor proportion score (TPS) of 50% or less who received new monotherapy with an ICI between July 2012 and December 2022 were retrospectively analyzed. Patients with response were compared with those without response in the post‐treatment response assessment.ResultsAmong the 37 patients, six (16.2%) NSCLC patients in the response group responded to ICI monotherapy and had a significantly lower body mass index (BMI) (p = 0.003). Significantly more patients in the response group developed immune‐related adverse events (irAEs) than in the nonresponse group (p < 0.001). Multivariate analysis identified high BMI as a significant independent risk factor predicting nonresponse to ICI monotherapy in NSCLC patients with PD‐L1 < 50%.ConclusionsAmong NSCLC patients with PD‐L1 < 50%, those with a higher BMI were more likely to be nonresponders to ICI monotherapy. In addition, the group that responded to ICI monotherapy may have been at higher risk of developing irAEs, suggesting that careful follow‐up is warranted.